R

Royalty Pharma plc

D
RPRX
USD
-0.23
(-0.8153%)
Market Closed
70,758.00
Volume
2.3015
EPS
2.94
Div Yield
18.653
P/E
12,538,720,936.88
Market Cap
Today
-0.8153%
1 Week
1.542%
1 Month
1.801%
6 Months
-7.320%
12 Months
2.098%
Year To Date
-0.427%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
F
FLXN
(%)
USD
M
MRNS
0.075
(4.918%)
USD
A
ARRY
-0.21
(-3.0792%)
USD
C
CYAN
(%)
USD
G
GLMD
1.29
(18.8873%)
USD
A
ARWR
0.35
(1.6851%)
USD
A
ALNY
3.06
(1.1203%)
USD
VRTX
VRTX
3.93
(0.8292%)
USD
E
EXEL
0.03
(0.1119%)
USD
I
INCY
1.67
(2.5625%)
USD

Title:
Royalty Pharma plc

Sector:
Healthcare
Industry:
Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Do you need help or have a question?
Contact Us